





Exploring patient characteristics and treatment in real-world endometrial cancer patients users of platinum therapy

Gabriela Abreu, PhD¹; Juliana Queiroz, MSc¹; Thiago Luiz Nogueira da Silva, PhD¹; Claudia Soares, MD, PhD¹; Patricia Menezes, MBA¹; Mariano Carrizo, MD²; Paula Scibona, MD³; Ventura A Simonovich, MD³; María C Riggi, MD³; Florencia Cravero, MD³; Laura Jotimliansky, MD²

¹GSK, Rio de Janeiro, Brazil; ²GSK, Buenos Aires, Argentina; ³Hospital Italiano de Buenos Aires, Buenos Aires, Argentina

ECHOS-A highlights that PBT (mainly carboplatin-paclitaxel) is a well-established 1L treatment option for patients with EC in Argentina, including during early stages of the disease



Background

- EC is the **sixth most common cancer** among women worldwide¹
- There are **limited** real-world data demonstrating the clinical characteristics of patients with EC, particularly in South America^{2,3}
- Understanding patients' clinical characteristics in this context is a **valuable approach** for highlighting unmet medical needs and **improving patient care**

Conclusion

- PBT** is a **well-established 1L treatment option** for EC, even in the early stages
- Carboplatin plus paclitaxel was the **most common 1L regimen**, used by almost three-quarters of patients
- Findings from ECHOS-A are important for understanding **clinical characteristics** and **real-world treatment patterns** in patients with EC in Argentina

Abbreviations

1L, first line; BMI, body mass index; EC, endometrial cancer; ECHOS-A, Endometrial Cancer Health Outcomes Study; FIGO, International Federation of Gynecology and Obstetrics; IQR, Interquartile range; PBT, platinum-based therapy; SD, standard deviation.

References

- World Cancer Research Fund International. <https://www.wcrf.org/cancer-trends/endometrial-cancer-statistics/> (accessed March 18, 2024);
- Bruggmann D et al. *J Transl Med* 2020;18:386;
- Paulino E and de Melo AC. *Rev Bras Ginecol Obstet* 2023;45:e401–e408.

Acknowledgements

Medical writing support was provided by Pallavi Patel, PhD, of Luna, OPEN Health Communications, and was funded by GSK, in accordance with Good Publication Practice (GPP) guidelines (www.ismpp.org/gpp-2022).

Disclosures

This study was funded by GSK (study ID: 221709). The authors declare the following real or perceived conflicts of interest during the past 3 years in relation to this presentation: GA, JQ, and TLNS are complementary employees of GSK and do not hold stocks or shares. CS, PM, MC, and LJ are employees of and hold stocks in GSK. MCR reports receiving speaker fees from AstraZeneca and GSK. PS, VAS, and FC have no conflicts of interest to declare.